Rosalind Advisors Inc. Buys Shares of 1,259,876 Fennec Pharmaceuticals Inc (NASDAQ:FENC)

Rosalind Advisors Inc. purchased a new stake in Fennec Pharmaceuticals Inc (NASDAQ:FENC) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,259,876 shares of the company’s stock, valued at approximately $7,962,000. Fennec Pharmaceuticals makes up 4.0% of Rosalind Advisors Inc.’s holdings, making the stock its 10th biggest position. Rosalind Advisors Inc. owned 4.57% of Fennec Pharmaceuticals at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Intech Investment Management LLC purchased a new stake in Fennec Pharmaceuticals during the 4th quarter worth about $69,000. Franklin Resources Inc. lifted its stake in shares of Fennec Pharmaceuticals by 18.7% in the 3rd quarter. Franklin Resources Inc. now owns 14,799 shares of the company’s stock valued at $74,000 after purchasing an additional 2,330 shares in the last quarter. Pinnacle Wealth Planning Services Inc. purchased a new position in Fennec Pharmaceuticals in the fourth quarter valued at approximately $97,000. Barclays PLC raised its stake in shares of Fennec Pharmaceuticals by 274.3% in the 3rd quarter. Barclays PLC now owns 31,319 shares of the company’s stock valued at $157,000 after acquiring an additional 22,951 shares during the period. Finally, Rhumbline Advisers lifted its stake in shares of Fennec Pharmaceuticals by 12.9% during the fourth quarter. Rhumbline Advisers now owns 34,299 shares of the company’s stock worth $217,000 after purchasing an additional 3,911 shares in the last quarter. Institutional investors and hedge funds own 55.51% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on FENC shares. HC Wainwright reissued a “buy” rating and set a $13.00 target price on shares of Fennec Pharmaceuticals in a research report on Tuesday, March 11th. Wedbush reissued an “outperform” rating and issued a $13.00 price objective on shares of Fennec Pharmaceuticals in a report on Monday, March 10th.

Fennec Pharmaceuticals Stock Up 0.8 %

NASDAQ:FENC opened at $6.67 on Friday. The business’s 50-day moving average price is $6.45 and its 200 day moving average price is $5.67. Fennec Pharmaceuticals Inc has a 52-week low of $3.96 and a 52-week high of $11.47. The firm has a market cap of $184.01 million, a P/E ratio of -66.69 and a beta of 0.36.

Insiders Place Their Bets

In other news, Director Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $6.79, for a total value of $67,900.00. Following the transaction, the director now owns 68,725 shares of the company’s stock, valued at $466,642.75. This trade represents a 12.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 31,186 shares of company stock valued at $203,389 over the last ninety days. Corporate insiders own 10.98% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.